Peter Lio, MD

Untreated or undertreated AD can lead to poor sleep, infections, and stunted development.

Current JAK inhibitors are approved only for those 12 and older, leaving younger patients without access.

In the first Derm Dispatch episode, Renata Block, MMS, PA-C, and Peter Lio, MD, discuss integrative approaches to managing eczema, including the use of holistic treatments.

Lio shared insights on minimizing pain in dermatologic procedures, highlighting practical techniques from his AAD 2025 presentations.

Lio emphasizes that patient comfort and understanding are essential for successful treatment outcomes.

A balanced approach to dermatologic care involves using steroids for flare-ups and switching to non-steroidal options for maintenance.

Explore the disease progression of atopic dermatitis and strategies to make a difference in patients' lives.

Lio discusses his SPD 2024 non-CME talk, new and exciting innovations in pediatric atopic dermatitis, and more.

Peter Lio, MD, explains the importance of having a wide-range of solutions and how he incorporates alternative approaches alongside conventional medicine.

Peter Lio, MD, expands on dosing considerations to treat atopic dermatitis with involvement on the hands and feet for different ages, weights, lifestyles, and more.

Peter Lio, MD, takes a deep dive into the results of the 3 LIBERTY-AD-HAFT study and how it impacts the treatment of hand-foot atopic dermatitis.

Lio spoke with Dermatology Times to discuss his sessions at AAD 2024, including addressing systemic malignancies with alternative or adjunctive therapies and the importance of minimizing pain in dermatology procedures.

Lio delves into his American Academy of Dermatology Annual Meeting session, "Dietary Triggers and Modifications of Common Dermatologic Conditions: An Evidence Based Approach."

An expert in the management of skin conditions highlights the case of a 45-year-old female with severe pruritus, erythematous rash, and lichenification across multiple body areas, worsened by recent work-related stress from a promotion. Dr. Lio offers insights into managing such patients and shares practical tips for a streamlined prescription process.

Peter Lio, MD, presents the case of a 56-year-old female with a history of severe atopic dermatitis and very dry skin. Dr. Lio discusses the significance of accurate disease diagnosis, tools for assessing severity, and the array of treatment options available for this patient. He emphasizes the importance of shared decision-making in managing the condition.

A patient with atopic dermatitis presents with redness and other unusual symptoms. What's the diagnosis?

Experts discuss prospective therapies on the horizon for atopic dermatitis (AD).

Experts offer their clinical experience on preventing patient withdrawal and breaking the atopic dermatitis (AD) disease cycle.

Peter Lio, MD also explained why he considers it a bad day when he does not learn something new about this disease.

Peter Lio, MD, FAAD, discusses how body surface area of atopic dermatitis (AD) affects topical treatment options.

Shawn Kwatra, MD, offers important considerations for providers when utilizing topical therapies for atopic dermatitis (AD).

Experts discuss the history and evolving landscape of topical steroids as therapy for atopic dermatitis (AD).

Peter Lio, MD, FAAD, and Shawn Kwatra, MD, discuss janus kinase (JAK) inhibitors and their recent use in the treatment of atopic dermatitis (AD).

Experts discuss the symptoms of atopic dermatitis (AD) and how disease severity may impact symptoms.

Shawn Kwatra, MD, and Peter Lio, MD, FAAD, discuss the burden of atopic dermatitis (AD) and how it may affect pediatric or adult patients.

Panelists share parting advice and key takeaways on the optimal management of atopic dermatitis within the treatment landscape.

Experts share insight on the challenges inherent in treating patients with atopic dermatitis despite recent advances in therapy.

Concluding their focused discussion on JAK inhibitors in atopic dermatitis, panelists share advice on the optimal selection based on route of administration and use of these agents.

A brief review of 2 oral JAK inhibitors recently approved for patients with atopic dermatitis.

A panel of experts review the use of topical ruxolitinib in atopic dermatitis, shedding light on safety and efficacy considerations.